Equity Overview
Price & Market Data
Price: $0.45
Daily Change: +$0.09 / 20.00%
Daily Range: $0.35 - $0.49
Market Cap: $14,682,504
Daily Volume: 21,102
Performance Metrics
1 Week: 3.52%
1 Month: -48.57%
3 Months: -80.77%
6 Months: -82.14%
1 Year: -61.21%
YTD: -55.45%
Company Details
Employees: 3
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.